Genmab — Marts 2019
-
Interesting discussion between Janssen and Nice last year
. Dara could reset MM treatment https://www.nice.org.uk/guidance/ta510/documents/committee-papers-2 -
Ja,, kunne der komme et bud , så de hurtigt ville i 0 ,, det ville glæde mig at de brændte nallerne lidt...
-
Desværre også på en grøn dag
-
Genmab og Novo følges ad med minus 0,22 og 0,26% i dag. Værre er det ikke.
-
GEN's kurs klargør blot at lægge sig favorabelt til os trofaste investorer, så vi kan full value, når vi skal brænde vores overskydende skat af lige om lidt!
-
New trial : Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV) https://clinicaltrials.gov/ct2/show/NCT03871829
-
and it looks like they will give this one another try https://clinicaltrials.gov/ct2/history/NCT03346135?A=5&B=6&C=merged
-
and the Tisotumab Vedotin safety study published the results
https://clinicaltrials.gov/ct2/history/NCT02552121?A=10&B=11&C=merged -
well , at least NICE itself also calls daratumumab a “potentially game-changing” treatment https://twitter.com/NICEcomms/status/1105468491388338176
-
They don't believe it has proved to be cost effective yet but : "The patient experts stated that the psychological benefit of delaying a second relapse had not been captured in the quality-of-life measure in the trial. The committee agreed that this had not been captured in the model."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind